Celldex reports Q2 EPS (85c), consensus (84c)

Reports Q2 revenue $730K, consensus $1.13M. “In the second quarter of 2025, data from our now completed Phase 2 study in chronic spontaneous urticaria were presented that we believe clearly show that barzolvolimab is best in disease and achieves the goal of treatment for patients and physicians-rapid, profound, durable complete response which is correlated with meaningful improvements in quality of life,” said Anthony Marucci, co-founder, president and CEO of Celldex (CLDX) Therapeutics. “The Celldex team is working diligently to bring this important medicine to patients and we remain focused on executing across our Phase 3 program in CSU, which is on track and expected to be fully enrolled next summer.”